Levodopa/benserazide

Levodopa/benserazide
Combination of
LevodopaDopamine agonist
BenserazideDecarboxylase inhibitor
Names
Trade namesProlopa, Madopar, others[1]
Other namesCo-beneldopa[2]
Clinical data
Main usesParkinson disease[2]
Side effectsAnxiety, depression, heart arrhythmias, hallucinations, low blood pressure with standing, loss of appetite, impulse control disorders, sudden sleepiness[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
    Routes of
    use    		By mouth
    Legal
    Legal status
    • AU: S4 (Prescription only) [3]
    • CA: ℞-only [4]
    • UK: POM (Prescription only) [5]
    • In general: ℞ (Prescription only)

    Levodopa/benserazide, also known as co-beneldopa and sold under the brand name Prolopa among others, is a combination medication used to treat Parkinson disease.[4][2] It is taken by mouth.[4]

    Common side effects include anxiety, depression, heart arrhythmias, hallucinations, low blood pressure with standing, and loss of appetite.[2] Other side effects can include impulse control disorders and sudden sleepiness.[2] It is not recommended in those with severe liver problems.[2] Stopping suddenly may result in severe muscle breakdown.[2] It is composed of levodopa, a dopamine agonist and benserazide, a decarboxylase inhibitor.[2]

    The combination was approved for medical use in Canada in 1977.[4] It is on the World Health Organization's List of Essential Medicines as an alternative to levodopa/carbidopa.[6] In the United Kingdom a 100 tablets costs the NHS about £10 as of 2023.[7]

    Medical uses

    Levodopa/benserazide is indicated for the treatment of Parkinson's disease with the exception of drug-induced parkinsonism.[3][4][5]

    Dosage

    The dose is based on the levodopa and range from 50 mg once per day to up to 800 mg in divided doses.[2]

    References

    1. ↑ "Levodopa". Archived from the original on 2023-02-28. Retrieved 2023-02-23.
    2. 1 2 3 4 5 6 7 8 9 10 "Co-beneldopa". BNF. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
    3. 1 2 3 "Archive copy". Archived from the original on 2023-01-09. Retrieved 2023-02-23.{{cite web}}: CS1 maint: archived copy as title (link)
    4. 1 2 3 4 5 "Prolopa Product information". Health Canada. 25 April 2012. Archived from the original on 2 March 2023. Retrieved 8 January 2023.
    5. 1 2 "Madopar 100 mg/25 mg Dispersible Tablets - Summary of Product Characteristics (SmPC)". (emc). 8 April 2020. Archived from the original on 28 February 2023. Retrieved 9 January 2023.
    6. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
    7. ↑ "Co-beneldopa Medicinal forms". BNF. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
    Identifiers:
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.